VRTX · Healthcare · $128.8B
After-hours $507.32+0.11%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“이번 분기 가장 큰 화제는 신장 질환 치료제 '포비타시셉트(Povi)'예요.”
In the company's words · 2026 1분기 earnings call